OBJECTIVE: Human immunodeficiency virus (HIV)-infected patients, especially those on antiretrovirals are at risk of cardiovascular disease (CVD). The haemorheologic and fibrinolgtic activity of treatment naïve Nigerian HIV-infected patients were investigated. METHODS: Blood was collected from 50 newly diagnosed treatment naïve HIV-infected patients and 50 apparently healthy HIV seronegative individuals that served as controls. Haematocrit values, plasma and serum viscosity, plasma fibrinogen concentration and euglobin lysis time were determined. RESULT: The mean +/- standard deviation of haematocrit value of HIV infected patients (31.70 +/- 6.33%) was significantly lower (p<0.0001) than those of controls (39.50 +/- 2.43%). The plasma serum viscosity, plasma fibrinogen concentration and euglobin lysis time of HIV-infected patients were significantly higher compared with those of controls (p<0.0001). CONCLUSION: Treatment naive Nigerian HIV-infected patients have a defective blood flow and fibrinolytic system, which may predispose them to CVD.
OBJECTIVE: Human immunodeficiency virus (HIV)-infectedpatients, especially those on antiretrovirals are at risk of cardiovascular disease (CVD). The haemorheologic and fibrinolgtic activity of treatment naïve Nigerian HIV-infectedpatients were investigated. METHODS: Blood was collected from 50 newly diagnosed treatment naïve HIV-infectedpatients and 50 apparently healthy HIV seronegative individuals that served as controls. Haematocrit values, plasma and serum viscosity, plasma fibrinogen concentration and euglobin lysis time were determined. RESULT: The mean +/- standard deviation of haematocrit value of HIV infectedpatients (31.70 +/- 6.33%) was significantly lower (p<0.0001) than those of controls (39.50 +/- 2.43%). The plasma serum viscosity, plasma fibrinogen concentration and euglobin lysis time of HIV-infectedpatients were significantly higher compared with those of controls (p<0.0001). CONCLUSION: Treatment naive Nigerian HIV-infectedpatients have a defective blood flow and fibrinolytic system, which may predispose them to CVD.
Authors: C Hadigan; J B Meigs; J Rabe; R B D'Agostino; P W Wilson; I Lipinska; G H Tofler; S S Grinspoon Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: Alisa Kim; Hajir Dadgostar; Gary N Holland; Rosalinda Wenby; Fei Yu; Brian G Terry; Herbert J Meiselman Journal: Invest Ophthalmol Vis Sci Date: 2006-09 Impact factor: 4.799
Authors: Larissa Tene; Claude T Tagny; Annick Mintya-Ndoumba; Victor N Fossi; Dora Mbanya Journal: Blood Coagul Fibrinolysis Date: 2014-07 Impact factor: 1.276
Authors: Fatai O Bello; Alani S Akanmu; Titilope A Adeyemo; Bukunmi M Idowu; Prosper Okonkwo; Phyllis J Kanki Journal: South Afr J HIV Med Date: 2021-08-23 Impact factor: 2.744
Authors: Aline A Petrilli; Suelen J Souza; Andrea M Teixeira; Patricia M Pontilho; José M P Souza; Liania A Luzia; Patricia H C Rondó Journal: Nutrients Date: 2016-05-23 Impact factor: 5.717